-
Ehrlich H J, Müller M, Fritsch S. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses[J]. J Infect Dis, 2009, 200(7): 1113-1118. doi: 10.1086/599179
-
European Union Health Security Committee (HSC)/Early Warning and Response System (EWRS). 2009. HSC/ EWRS statement on influenza A(H1N1) 2009: target and priority groups for vaccination. http://ec.europa.eu/health/ph_threats/com/Influenza/docs/HSC_EWRS_statement_en.pdf
-
Jain F S, Finelli L, Shaw M W. Emergence of a novel swine-origin influenza A (H1N1) virus in humans[J]. N Engl J Med, 2009, 360(): 2605-2615. doi: 10.1056/NEJMoa0903810
-
Johansen K, Nicoll A, Ciancio B C. Pandemic influenza A(H1N1) 2009 vaccines in the European Union[J]. Euro Surveill, 2009, 14(41): 19361-.
-
Katz J, Hancock K, Veguilla V. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine[J]. MMWR Morb Mortal Wkly Rep, 2009, 58(): 521-524.
-
Li J, Shao T J, Yu X F, Pan J C. Molecular evolution of HA gene of the influenza A H1N1 pdm09 strain during the consecutive seasons 2009-2011 in Hangzhou, China: Several immune-escape variants without positively selected sites[J]. J Clin Virol, 2012, (): -.
-
Lin J, Zhang J, Dong X. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial[J]. Lancet, 2006, 368(): 991-997. doi: 10.1016/S0140-6736(06)69294-5
-
Maher J A, DeStefano J. The ferret: an animal model to study influenza virus[J]. Lab Anim (NY), 2004, 33(): 50-53. doi: 10.1038/laban1004-50
-
Mamadalyiev S, Nurpeysova A, Khairullin B. Preclinical Testing of Refluvac®, A vaccine against pandemic influenza A/H1N1v[J]. J Appl Environ Biol Sci, 2011, 1(3): 48-53.
-
Ninomiya A, Imai M, Tashiro M. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model[J]. Vaccine, 2007, 25(): 3554-3560. doi: 10.1016/j.vaccine.2007.01.083
-
Palmer D F, Dowdle W R, Coleman M T. Advanced laboratory techniques for influenza diagnosis[J]. Immun Ser, 1975, 6(): 25-45.
-
Pascua P N Q, Song M-S, Lee J H. Evaluation of the efficacy and cross-protectivity of recent human and swine vaccines against the pandemic (H1N1) 2009 virus infection[J]. PLoS ONE, 2009, 4(12): e8431-. doi: 10.1371/journal.pone.0008431
-
Reed L J, Muench H. A simple method of estimating fifty percent endpoints[J]. Am J Hyg, 1938, 27(): 493-497.
-
Ruat C, Caillet C, Bidaut A. Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement[J]. J Virol, 2008, 82(): 2565-2569. doi: 10.1128/JVI.01928-07
-
Subbarao K, Luke C. H5N1 viruses and vaccines[J]. PLoS Pathog, 2007, 3(3): e40-. doi: 10.1371/journal.ppat.0030040
-
Vajo Z, Kosa L, Visontay I. Inactivated Whole Virus Influenza A (H5N1) Vaccine[J]. Emerg Infect Dis, 2007, 13(5): 807-808. doi: 10.3201/eid1305.061248
-
WHO. 2010. Pandemic (H1N1) 2009: update 106. http://www.who.int/csr/don/2010_06_25/en/index.html.
-
WHO. 2002. WHO manual on animal influenza diagnosis and surveillance. Geneva: World Health Organization.
-
Wood J M, Schild G C, Newman R W. An improved single radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines[J]. J Biol Stand, 1977, 5(): 237-247. doi: 10.1016/S0092-1157(77)80008-5
-
Zimmer S M, Burke D S. Historical perspective -emergence of influenza A(H1N1) viruses[J]. N Engl J Med, 2009, 361(): 279-285. doi: 10.1056/NEJMra0904322